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Abstract
Objective: Intra-Articular (IA) injection of polyacrylamide hydrogel (PAAG) is a possible treatment for symptomatic Osteoar-
thritis (OA) of the knee. This study evaluated the efficacy and safety of a single injection of 6 ml intra-articular PAAG over 26 
weeks.
Methods: Open-label study in patients with symptomatic and radiographically confirmed knee OA . Primary outcome was 
change in WOMAC pain after 13 weeks. Secondary outcomes were WOMAC stiffness and function subscales, Patient Global 
Assessment of disease impact (PGA) and proportion of OMERACT-OARSI responders. Follow-up time points were 4, 13 and 
26 weeks.
Results: 49 patients (31 females) received PAAG, with 48 patients completing the 13 and 46 the 26 weeks assessments. Mean 
change in WOMAC pain after 13 weeks was -18.3 points [95% CI-23.4 to -13.3]; P<.0001 and at 26 weeks -20.8 points [95% 
CI -26.3 to -15.3]; P<0.0001 with similar benefits for WOMAC stiffness, physical function, and PGA. After 13 weeks 64.6% 
were OMERACT-OARSI responders and this was maintained at 26 weeks.. During the 13 weeks, 18 patients reported 23 adverse 
events, 13 of which were related to PAAG, none severe. Two serious adverse events, atrial fibrillation and gastrointestinal pain, 
were assessed as ‘not related’ to PAAG.
Conclusions: PAAG can be delivered in a single 6 ml injection and this non-randomized trial in patients with knee OA demon-
strated beneficial clinical effects at 13 and 26 weeks. No serious adverse events were seen with PAAG. These encouraging results 
need to be confirmed in controlled studies.
Keywords: Intra-articular treatment; Osteoarthritis
Background
Osteoarthritis (OA) is the most common arthritis, 
characterised by pain and physical disability [1]. More than 10% of 
persons 55 years of age or older have symptomatic OA, primarily 
involving the knees [2]. Although several treatment options for 
OA in the knee are available, non-pharmacological treatments 
(e.g. exercise, weight loss if overweight) are often underutilised, 
analgesics have limited benefits, and joint replacement surgery is 
limited to end-stage disease. New treatment options are therefore 
warranted in order to improve the care of people with OA. Recently, 
Intra-Articular (IA) injection of polyacrylamide gel (PAAG) has 
been suggested as a possible treatment for symptomatic OA. 
PAAG is a proprietary 2.5% cross-linked polyacrylamide hydrogel, 
manufactured by Contura International A/S. PAAG contains 2.5% 
polyacrylamide and 97.5% non-pyrogenic water, with a unique 
molecular structure that allows normal water exchange with the 
surrounding tissue without losing shape. PAAG is biocompatible, 
non-absorbable, non-biodegradable, and structurally stable. For 
more than 20 years, PAAG has been used for various indications 
such as bulking for stress urinary incontinence and soft tissue 
augmentation. PAAG is classified as a Class IIb device under the 
European Council Directive 93/42/EEC on medical devices.
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PAAG has been extensively tested in horses with OA with 
pain relief observed within a month, with the majority of the horses 
no longer being lame after 24-months [3]. An observational study 
in patients with knee OA reported that IA PAAG delivered as two 
injections of 3 ml separated by 1 month provided symptomatic 
relief up to 13 months [4]. If 6 ml can be delivered in one treatment 
session, this would improve patient acceptability, feasibility of 
treatment and reduce the risk of potential side effects related to 
repeated injections. The objectives of this study were to evaluate 
the efficacy and safety of one injection of 6 ml IA PAAG on knee 
pain in patients with moderate to severe knee OA.
Methods
This study was an open label, 26-week observational study 
of the efficacy and safety of intra-articular (IA) injection of PAAG 
with data collected from August 2019 to April 2020 at three clinical 
sites in Denmark. The protocol for this study was approved by the 
local Health Research Ethics committee (ref.no: H-19031685), the 
Danish Health authorities, and was registered at www.clinicaltrials.
gov (NCT04179552) before any study related activities. Patients 
gave informed consent prior to participation, and the study was 
conducted according to the principles of good clinical practice. 
Inclusion criteria were: adults with a clinical diagnosis of knee 
OA according to the American College of Rheumatology, definite 
radiographic OA in the target knee (Kellgren-Lawrence grade 2-4) 
(locally read), score of ≥2 (on 0-4 scale) on the Western Ontario 
and McMaster Universities Osteoarthritis Index (WOMAC) 
question related to pain while walking on a flat surface, a body 
mass index (BMI) <35 kg/m2, and, if patients were taking oral 
analgesics, they needed to have been on a stable dose for at least 
4 weeks prior to inclusion. Exclusion criteria included: previous 
IA PAAG treatment, IA hyaluronic acid or its derivatives in target 
knee within prior 6 months, IA corticosteroids within 3 months, 
skin disease in the injection area, and surgery in the treatment knee 
within 6 months.
The patients received one treatment of 6 ml PAAG and 
attended clinical follow-up visits after 4, 13, and 26 weeks.
Treatments Administered
PAAG was provided in sterile, pre-filled 1 ml sealed 
syringes to be injected IA with a sterile 21G x 2-inch (0.8 x 50 
mm) needle. Each patient received one IA injection of PAAG 
(6ml) under ultrasound guidance to ensure proper placement of 
the bolus inside the joint cavity. Prior to the injection, prophylactic 
antibiotics were given and topical anaesthetics were applied. Once 
the needle was inserted, the prefilled 1 ml PAAG syringes were 
changed via the Luer lock system to reach a total of 6 ml of PAAG 
with the needle remaining in place. Analgesic treatment with 
nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol 
was allowed during the trial, but not exceeding the recommended 
dosage (e.g. paracetamol up to 4000 mg/day and ibuprofen 1200 
mg/day), but not allowed within 48 hours prior to a study visit. 
Non-pharmacological therapy was allowed if kept stable during 
the study. All concomitant therapies and treatments were recorded. 
Outcomes
The primary outcome measure was change from baseline in 
the pain subscale of the WOMAC at 13 weeks. Secondary outcome 
measures were changes in baseline in the physical function and 
stiffness subscales of WOMAC, Patient’s Global Assessment 
(PGA) of OA impact, and the proportion of positive responders to 
the OMERACT-OARSI response criteria [5]. Data were collected 
at baseline, and after 4, 13, and 26 weeks. In this study, the Danish 
WOMAC was used in the 5-point Likert format with scores ranging 
from 0 (indicating no pain, stiffness, or difficulty) to 4 (indicating 
extreme pain, stiffness, or difficulty). The three WOMAC subscale 
scores were normalised to a 0-100 scale with 0 indicating best 
outcome and 100 indicating worst outcome. The PGA was based on 
responses to the question “How much does the knee osteoarthritis 
(treatment knee) as a whole affect your life at present?” indicated 
on a 100 mm Visual Analogue Scale (VAS) with anchors 0 = “Not 
at all” and 100 = “The worst imaginable”. OMERACT-OARSI 
response was defined as either (1) improvement in WOMAC pain 
or physical function ≥50% and an absolute change ≥20 normalised 
units (0-100); or (2) ≥20% improvement and an absolute change 
≥10 points two of the three categories: WOMAC pain, WOMAC 
physical function, and PGA.
Statistical Methods
The sample size was calculated to detect a change of at least 
12 points on the WOMAC pain subscale (0-100 points) using 
a one-sample t-test and a statistical significance level of 0.05, 
assuming a common standard deviation of 22 points. To obtain 
90% power a sample size of 38 was required. The analyses of the 
primary outcome were performed by using a repeated measures 
mixed linear model with a restricted maximum likelihood based 
approach and carried out on the full analyses set population defined 
as patients who received study treatment as per the protocol and 
who had a valid recording of the WOMAC pain subscale at 
baseline. Missing data were not imputed but handled implicitly 
by the repeated measures mixed linear model. The analyses of the 
secondary outcomes were performed using the same statistical 
model as for the primary outcome applied to the same population 
defined as all allocated subjects who received study treatment. 
The proportion of positive responders to the OMERACT-OARSI 
criteria at time points 4 weeks, 13 weeks, and 26 weeks were 
summarised including exact Clopper-Pearson 95% confidence 
intervals. Internationally applicable estimates of minimal clinically 
important improvements (MCII) of the WOMAC scores on the 
0-100 scale have been suggested for individuals with knee OA in 
a 4-week study of nonsteroidal anti-inflammatory drugs [6]. For 
the WOMAC pain subscale the MCII is 9 points; for the stiffness 
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subscale MCII it is 7 points; and for the function subscale MCII it 
is 6 points. For transformed WOMAC pain, stiffness and physical 
function subscales the proportion of subjects fulfilling the MCII 
criteria at week 26 were summarised including exact Clopper-
Pearson 95% confidence intervals. 
Results
50 subjects (31 females, mean age 70 SD 9 years) were 
screened and 49 enrolled in the study (Table 1). One subject 
received only approximately 5 ml of PAAG due to a user error; 
thus, the full analysis set consisted of 48 subjects. All 48 subjects 
completed the 4 and 13 week assessments, and 46 completed the 
week 26 assessment.
Table 2 shows the results from the main analyses. At the 
13 weeks follow-up there was a decrease in the WOMAC pain 
score of -18.3 points (95% CI -23.3 to -13.3; P<.0001). This was 
further improved at 26 weeks to -20.8 (95% CI -26.2 to -15.3; 
P<.0001). Similar results were found for the WOMAC stiffness 
and function subscales, which improved at the 4, 13 and 26 week 
assessments. WOMAC pain, stiffness and function subscales data 
at the 26-week assessment are provided in Figure 1. At 4, 13 and 
26 weeks, the PGA had decreased by -13.4 mm (95% CI -19.5 to 
-7.3; P<.0001); -18.7 mm (95% CI -25.3 to -12.1; P<.0001), and 






ITT analysis set 49 (100.0)
Full analysis set 48 ( 98.0)
Per protocol analysis set 41 ( 83.7)
 
Withdrawn until 26 weeks 3 (  6.1)
 Adverse event 1 ( 33.3)
 Withdrawal by subject 2 ( 66.7)
 
Completers of 26 weeks 46 ( 93.9)
N: Number of subjects; %: Percentage of subjects
Table 1: Subject disposition.
WOMAC Pain subscale WOMAC Stiffness subscale WOMAC Physical function subscale





Full analysis set 
(N,%) 49 (100.0)
Baseline 
N 49 49 49
Mean (SD) 50.3 (11.8) 55.6 (17.5) 46.6 (16.1)
Median 50.0 62.5 45.6
Min - Max 20 - 75 0 - 88 9 - 87
Week 4 
N 49 49 49 49 49 49
Mean (SD) 34.9 (16.4) -15.4 (15.3) 44.1 (20.6) -11.5 (17.3) 33.4 (16.7) -13.2 (13.8)
LSMean -15.4 -11.4 -13.2
95% CI (-19.7; -11.2) (-16.2; -6.6) (-16.9; -9.6)
Median 35.0 -15.0 50.0 -12.5 35.3 -10.3
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WOMAC Pain subscale WOMAC Stiffness subscale WOMAC Physical function subscale





Min - Max 0 - 75 -50 - 15 0 - 88 -50 - 38 1 - 63 -38 - 22
Week 13 
N 48 48 48 48 48 48
Mean (SD) 32.1 (18.2) -18.0 (18.5) 34.6 (21.0) -20.8 (19.9) 29.4 (18.0) -17.1 (16.1)
LSMean -18.3 -21.0 -17.2
95% CI (-23.4; -13.3) (-26.4; -15.7) (-21.5; -12.9)
Median 35.0 -20.0 25.0 -25.0 28.7 -19.8
Min - Max 0 - 75 -55 - 35 0 - 75 -63 - 38 0 - 60 -44 - 25
Week 26 
N 46 46 46 46 46 46
Mean (SD) 28.9 (18.6) -21.7 (19.6) 37.2 (21.5) -17.9 (21.2) 28.6 (20.3) -18.4 (17.0)
LSMean -20.8 -17.5 -18.0
95% CI (-26.3; -15.3) (-23.3; -11.8) (-23.0; -13.1)
Median 30.0 -22.5 31.3 -18.8 28.7 -20.6
Min - Max 0 - 70 -60 - 25 0 - 75 -50 - 50 0 - 62 -47 - 21
N: Number of subjects, SD: Standard deviation; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index
Table 2: Summary of transformed WOMAC pain subscale (0-100) - 26 weeks ITT analysis set.
Figure 1: Mean plot of transformed WOMAC pain subscale (0-100) - 26 weeks - ITT analysis set.
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The proportion of OMERACT-OARSI responders at the 4, 13 and 26 week assessments were 53.1%; (95% CI 38.3 to 67.5); 64.6% 
(95% CI 49.5 to; 77.8), and 67.4% (95% CI 51.98 to 80.47), respectively. The proportion of patients with a response larger than the MCII 
in the transformed WOMAC subscales at week 26 was highest for the WOMAC pain subscale (78%) but was greater than 70% for all 3 
subscales (Table 3).
N n (%) (95% CI)
ITT analysis set 49
Transformed WOMAC pain 
subscale 46 36 ( 78.3) ( 63.6 ;  89.1)
Transformed WOMAC stiffness 
subscale 46 34 ( 73.9) ( 58.9 ;  85.7)
Transformed WOMAC physical 
function subscale 46 34 ( 73.9) ( 58.9 ;  85.7)
N: Number of subjects, n: number of subjects achieving the minimal clinically important improvements (MCII) on the WOMAC subscales
MCII: Change in WOMAC pain ≤ -9, Change in WOMAC stiffness ≤ -7, Change in WOMAC physical function ≤ -6
CI: Clopper-Pearson exact confidence interval for the proportion
Table 3: Summary of minimal clinically important improvements for WOMAC subscales - 26 weeks.
Safety
Twenty-one participants reported a total of 31 adverse events (AEs) during the 26-week study period, of which 14 events were 
assessed to be related to PAAG (Table 4). 12 events (in 11 patients) were musculoskeletal and connective tissue disorders with 11 events 
being in the treated knee. The most frequently treatment related AEs were arthralgia (7 events), joint swelling (3 events) and synovial 
cysts (2 events). Almost all treatment related AEs were mild, with 3 classified as moderate (Table 5). Two events were reported as serious 
adverse events (SAEs): 1 hospitalisation with atrial fibrillation and 1 hospitalisation with abdominal pain; neither were assessed as 
related to the device. No deaths were reported, and no AE led to withdrawal from the study (Figures 2,3).
PAAG-OA 
N (%) E
ITT analysis set 49
Adverse events (AEs) 20 ( 40.8)  27
Serious AEs 2 (  4.1)   2
Non-serious AEs 20 ( 40.8)  25
Treatment emergent AEs (TEAEs) 20 ( 40.8)  27
Non-treatment emergent AEs 0
Adverse device effects (ADEs) 12 ( 24.5)  15
Serious ADEs (SADEs) 0
AEs leading to withdrawal from study 0
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Mild 17 ( 34.7)  22
Moderate 5 ( 10.2)   5
Severe 0
Outcome 
Recovered/resolved 12 ( 24.5)  14
Not yet recovered 0
Recovering/resolving 9 ( 18.4)  10
Not recovered/not resolved 3 (  6.1)   3
Unknown 0
Relationship to medical device 
Not Related 9 ( 18.4)  12
Unlikely 5 ( 10.2)   6
Possibly 6 ( 12.2)   6
Probably 2 (  4.1)   2
Related 1 (  2.0)   1
N: Number of subjects experiencing the event at least once, 
%: Percentage of subjects
E: Total number of reporting of the event
Adverse events with start date no later than the visit 4 date or withdrawal date in case of withdrawal before visit 4 are included
Table 4: Adverse events - 26 weeks.
System organ class 




ITT analysis set (N %) 49 (100.0)
 
Any adverse events 20 ( 40.8)  27
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Musculoskeletal and connective tissue disorders 15 ( 30.6)  17
Arthralgia 8 ( 16.3)   8
Joint swelling 3 (  6.1)   3
Synovial cyst 2 (  4.1)   2
Back pain 1 (  2.0)   1
Bursitis 1 (  2.0)   1
Joint effusion 1 (  2.0)   1
Pain in extremity 1 (  2.0)   1
 
Gastrointestinal disorders 2 (  4.1)   2
Abdominal pain 1 (  2.0)   1
Gastrooesophageal reflux disease 1 (  2.0)   1
 
Infections and infestations 2 (  4.1)   2
Nasopharyngitis 1 (  2.0)   1
Skin infection 1 (  2.0)   1
 
Cardiac disorders 1 (  2.0)   1
Atrial fibrillation 1 (  2.0)   1
 
Injury, poisoning and procedural complications 1 (  2.0)   1
Upper limb fracture 1 (  2.0)   1
 
Metabolism and nutrition disorders 1 (  2.0)   1
Diabetes mellitus 1 (  2.0)   1
 
Not coded 1 (  2.0)   1
N: Number of subjects experiencing the event at least once, 
%: Percentage of subjects
E: Total number of reporting of the event
Adverse events with start date no later than the visit 4 date or 
withdrawal date in case of withdrawal before visit 4 are included
Table 5: Treatment emergent adverse events by system organ class and preferred term -26 weeks - ITT analysis set.
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Figure 2: Mean plot of transformed WOMAC stiffness subscale 
(0-100) - 26 weeks - ITT analysis set.
Figure 3: Mean plot of transformed WOMAC physical function 
subscale (0-100) - 26 weeks.
Discussion
This open label study in patients with knee OA who received 
6 ml PAAG administered as one IA injection showed significant 
improvement in the WOMAC pain subscale at 4 and 13 weeks 
which were sustained at 26 weeks. A high percentage of patients 
achieved MCII at all time points. This was accompanied by 
improvements in the WOMAC stiffness and function, as well as 
in the PGA, and two thirds of patients were OMERACT-OARSI 
responders, demonstrating the efficacy of IA PAAG. PAAG has non-
absorbable, non-biodegradable and non-migratory characteristics. 
Upon injection into the joint cavity, the hydrogel integrates with 
synovial cells which then proliferate, ultimately re-establishing 
the synovial lining [7,8]. As the synovial membrane is highly 
innervated with nociceptive nerve fibres, this re-establishment of 
synovium may explain the beneficial effects on pain and other OA 
symptoms. Although speculative, the action on pain may be via an 
antiinflammatory effect on the synovium. 
The 13 week efficacy outcomes of the single 6 ml injection 
in this study are similar to the 4 month outcomes of a previously 
reported observational study where 2 separate injections of 3 ml 
were tested [4]. Relatively few adverse events were reported in 
both studies, and all device related AEs were assessed as mild or 
moderate. In this series, no acute inflammatory adverse reactions 
was experienced to the injection. However, if such were to occur, 
the immediate treatment would follow the RICE priniciple (rest, 
ice, elevation) or, in case of excess joint fluid, aspiration. The 2 
reported SAEs were assessed as not related to the device. Thus, 
the overall findings suggest that the clinical application of PAAG 
is safe and effective and can be conducted as a single injection, 
thereby simplifying the treatment strategy. This study is limited 
by the lack of a control group, which introduces a risk of bias to 
the results. However, it was designed to detect therapy effects 
as experienced by the patients and the results are indicative of a 
considerable benefit following treatment with PAAG, reflecting 
similar results seen in a previous study [4,9]. Nevertheless, a 
randomised, controlled study is needed to confirm the clinical 
efficacy and its role in managing patients with knee OA.
Conclusion
In conclusion, this study in patients with knee OA suggests 
that 6 ml PAAG can be delivered in a single session with good 
clinical effects at 26 weeks follow up with no safety concerns 
raised. The outcomes appear promising but need to be confirmed 
in a randomized, controlled study.
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